Pharma and biotech companies are increasing their reliance on genetically engineered rodent models of human disease in order to improve their chances of clinical success. These highly customized mice and rats offer precise modelling for basic research, target validation, and safety assessment. However, no matter the research area, there are a several factors to consider in order to reach timeline goals and generate reproducible results.
This webinar takes an in-depth look at:
- Important decisions on species, strain, and technologies
- Improving translatability and efficacy from concept to clinic
- Cutting-edge science relating to gene editing, humanized rodents, and more
Joseph A. Cornicelli, PhD, FAHA
Senior Director, In Vivo Pharmacology
Jean Cozzi, PhD
Innovation Manager, Genetically Engineered Models and Services
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.